

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4)

Thomas Pickering, M.D.

Committees: Endocrinologic & Metabolic Drugs and the Drug Safety and Risk Management Advisory Committees

Meeting Dates: July 30, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the discussions of the cardiovascular ischemic/thrombotic risks of the thiazolidinediones, with focus on rosiglitazone, as presented by the FDA and GlaxoSmithKline. I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

I am also eligible to receive a waiver under 21 U.S.C. §355 (n)(4). I understand that this financial interest did not require an individual waiver under 18 U.S.C. 208(b)(3) as the interests are in publicly traded securities less than \$25,000 in aggregate and thus covered by a regulatory exemption issued by the Office of Government Ethics at 5 CFR 2640.202.

Type of Interest	Nature	Magnitude
Advisory Board	Competing Firm	Less than \$10,001 per year
Stocks	Competing Firms	Stocks are valued from \$5,001 to \$25,000 in aggregate

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

/S/
Signature of SGE

6/21/2007
Date